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Antibody-based therapies are currently evaluated for treatment of
several severe diseases, such as cancer, viral infections and
autoimmunity. Recent technological improvements have made it
possible to clone and produce large amounts of intact recombi-
nant monoclonal antibodies or antibody fragments with unique
specificities (reviewed by Winter and Milstein, 1991; Dall’Acqua
and Carter, 1998; Hudson, 1998). Several tumour-associated
antigens have been identified and are currently being investigated
as therapeutic targets for haematological and solid tumours
(Riethmüller et al, 1993). non-small-cell lung cancer (NSCLC) is
an aggressive solid tumour associated with a poor prognosis since
surgery or chemotherapy is only beneficial in a fraction of all
cases. Antibody-based therapy has been of limited success, but
has been described using murine antibodies against targets such
as the EGF-receptor in squamous cell carcinoma (Modjtahedi
et al, 1996) or epithelial glycoprotein-2 for adenocarcinoma
(Zimmermann et al, 1997). Such monoclonal antibodies probably
may act by interfering in tumour cell signalling or through activa-
tion of complement and/or Fc receptor bearing cells. To potentiate
the effects of monoclonal antibodies, the use of fusions with
superantigens, which are of bacterial or viral origin and activate T
cells by linking the T cell receptor to MHC class II on antigen
presenting cells (reviewed by Johnson et al, 1992), have
previously been described by us (Dohlsten et al, 1994; Brodin
et al, 1998). Thereby, large amounts of cytotoxic and cytokine
producing T-cells can be targeted to destroy and initiate a powerful
T cell attack against tumour cells in vivo (Dohlsten et al, 1994,
1995a). Most studies of antibody targeted superantigens, e.g.
staphylococcal enterotoxin A, SEA, have been for the treatment of
human colorectal cancer (Dohlsten et al, 1995b). However, to
decrease the reactivity of the superantigen with MHC class II-
bearing cells, the Asp227Ala replacement were introduced to
destroy the site having the highest affinity for MHC class II in
SEA (Abrahmsén et al, 1995). 
The human 5T4 antigen was discovered by looking for shared
surface molecules which would reflect the functional similarities
between the growth and invasive properties of trophoblast, the
major interfacing cell type between mother and fetus in the
placenta, and tumour cells. The murine antibody 5T4 recognizes a
72 kDa glycoprotein (Hole and Stern, 1988, 1990) found in many
carcinomas, especially non-small-cell lung and breast cancer, but
at low levels in normal tissues (Southall et al, 1990). 5T4 tumour-
associated labelling is also a marker of prognostic significance in
colorectal (Starzynska et al, 1992, 1994, Mulder et al, 1997) and
gastric carcinoma (Starzynska et al, 1998). The cDNA encoding
human 5T4 predicts a heavily glycosylated membrane-bound
protein with regions containing leucine rich repeats, which prob-
ably contribute directly to protein–protein interactions (Myers
et al, 1994). Overexpression of 5T4 antigen alters cell adhesion,
shape and motility in vitro (Carsberg et al, 1995, 1996). Minimal
residual disease is likely to be 5T4 positive and is thus a potential
candidate for superantigen mediated therapy. Here, the potential
for a fusion protein between 5T4 and SEAD227A was investigated
for therapy of NSCLC. 
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Summary Superantigens activate T-cells by linking the T-cell receptor to MHC class II on antigen-presenting cells, and novel reactivity can be
introduced by fusing the superantigen to a targeting molecule. Thus, an antibody-targeted superantigen, which activates T cells to destroy tumour
cells, might be used as cancer therapy. A suitable target is the 5T4 oncofetal antigen, which is expressed on many carcinomas. We constructed a
fusion protein from a Fab of a monoclonal antibody recognizing the 5T4 antigen, and an engineered superantigen. The recombinant product
5T4FabV13-SEAD227A bound the 5T4 antigen expressed on the human non-small-cell lung cancer cell line Calu-1 with a Kd of 1.2 nM while the
substitution of Asp227 to Ala in the superantigen moiety reduced binding activity to MHC class II. 5T4FabV13-SEAD227A tumour reactivity was
demonstrated in 7/7 NSCLC samples by immunohistochemistry, while normal tissue reactivity was low to moderate. 5T4FabV13-SEAD227A induced
significant T-cell-dependent in vitro killing of sensitive 5T4 bearing Calu-1 cells, with maximum lysis at 10–10 M, while the capacity to lyse MHC class
II expressing cells was approximately 1000 times less effective. Immunotherapy of 5T4FabV13-SEAD227A against human NSCLC was investigated
in SCID mice reconstituted with human peripheral blood mononuclear cells. Mice carrying intreperitoneally growing Calu-1 cells showed significant
reduction in tumour mass and number after intravenous therapy with 5T4FabV13-SEAD227A. Thus, 5T4FabV13-SEAD227A has highly attractive
properties for therapy of human NSCLC. © 2001 Cancer Research Campaign http://www.bjcancer.com
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Cells 
The 5T4 hybridoma was grown and the mAb purified as previ-
ously described (Hole and Stern, 1990). The human leukaemia cell
line K562, colon adenocarcinoma WiDR, HT29, NSCLC Calu-1,
ME 180 and the B cell lymphoblastoid Raji were obtained from
American Type Culture Collection (Rockville, MD). All cells
were mycoplasma free and maintained under standard conditions. 
Peripheral blood mononuclear cells, PBMC, were from
heparinized blood from normal donors at the University Hospital
of Lund. The cells were isolated by density centrifugation over
Ficoll-Paque cushion and incubated in complete R-medium
(RPMI-1640 supplemented with 10% fetal calf serum (Gibco
BRL, Life Technologies, UK), 1 mM glutamine, 10 mM Hepes
buffer, 1 mM sodium pyruvate (HyClone Europe, UK), 50 mM 2-
mercaptoethanol (ICN Biomedicals INC. Costa Mesa CA), 0.1 M
NaHCO3 (Seromed Biochrome), 0.1 mg ml–1 gentamycine
(Biological Industries, Kibbutz Beit Haemek, Israel). SEA acti-
vated T cell lines were produced by activation of PBMC using 2 ´
106 cells ml–1 with mitomycin C-treated BSM cells preincubated
with 100 ng ml–1 SEA in medium with 10% FCS (Dohlsten et al,
1991). The T cell lines were restimulated biweekly with 20 U ml–1
IL-2, weekly with mitomycin C treated SEA coated BSM cells
(Van De Griend et al, 1984) and cultivated for 4–12 weeks before
being used in the assay. The viability of the effector cells, as deter-
mined by trypan blue exclusion, exceeded 50%. Flow cytometric
analysis and sorting were performed according to standard setting
on a FACStarPlus (Becton Dickinson, Mountain View, CA, USA). 
Cloning, expression and purification of Fab-SEA fusion
proteins 
The fusion proteins were produced at Pharmacia & Upjohn
(Stockholm, Sweden) essentially as described (Dohlsten et al,
1994; Abrahmsén et al, 1995; Forsberg et al, 1997). The Fv-
encoding portions of 5T4 were cloned from the 5T4 hybridoma
and fused to sequences coding for the constant regions of the
murine IgG1/k antibody C242 lacking the interchain disulphide
bond. A region coding for SEAD227A was connected to the C-
terminus of the heavy chain (Figure 1A) via a Gly-Gly-Pro linker.
The products were expressed and secreted in the E. coli K-12
strain UL 635 (xyl-7,  ara-14, T4R,  DompT) (Abrahmsén et al,
1995) using a plasmid with a lacUV5-promoter. After fermenta-
tion, clarified growth medium was applied to a Protein G
Sepharose column (Pharmacia Biotech, Uppsala, Sweden) and
bound protein eluted with 0.1 M acetic acid, 0.05% Tween 80.
Full-length product was separated from a degraded variant lacking
the superantigen moiety, 5T4FabV13, on an SP Sepharose HP
column (Pharmacia Biotech) using a linear gradient from 60 to
350 mM sodium acetate (Forsberg et al, 1997). SDS-PAGE and
chromatographic techniques indicate that the purity of the product
was at least 95%. 
Assays 
To measure lymphocyte proliferation by incorporation of [3H]-
thymidine, 2 ´105PBMC were incubated at 37˚C in 200 ml complete
R-medium with titrating amounts of Fab-SEA proteins for 72 h, as
described (Dohlsten et al, 1988). Tumour cell growth-inhibition
assay were performed using 5 ´ 103 tumour cells well in 96-well
flat-bottomed microtitre wells (Nunc, Roskilde, Denmark) in
complete R-medium and titrating dilutions of supernatants from
PBMC incubated for 72 h with 10–9 M of Fab-SEA fusion proteins
in a total volume of 200 ml. Tumour cells were then incubated for
72 h and the viable fraction of cells determined using the MTT-
assay (Van de Loosdrecht et al, 1991). The production of IL-2,
IFN-g and TNF-a in 2 ´ 106 PBMC ml–1 incubated at 37˚C with
titrating amounts of Fab-SEA proteins, were measured in culture
supernatants from plates in 2 ml R-medium with specific ELISA
reagents (Genzyme Corporation, Cambridge, MA) as recom-
mended by the supplier. 
To study cytotoxicity, K562, Calu-1 or Raji cells, labelled with
(Na)2
51 CrO4 (Amersham Solna, Sweden) were used in a standard
4 h chromium release assay (Dohlsten et al, 1994). As effector
cells, an SEA reactive T cell line, prepared as described above,
was used. This cell line contains more than 99% CD3-positive
cells (Hedlund et al, 1990). The specific cytotoxicity was calcu-
lated using the average counts/min (cpm) in the formula: specific
cytotoxicity = (experimental cpm – spontaneous release cpm)/
(total release cpm – spontaneous release cpm). 
Binding assays 
Affinities to the 5T4 antigen were measured similarly to Forsberg
et al (1997). 5T4FabV13-SEAD227A and 5T4FabV13 respectively
were labelled with Na125I (NEN, Boston, MA) to obtain a specific
activity of 10 to 40 mCi mg–1 protein and an iodine to protein ratio
of ≤ 2:1. Serially diluted 125I-labelled 5T4FabV13-SEAD227A or
5T4FabV13 in triplicate was incubated with Calu-1 or ME 180
cells for 2 h at room temperature. After washing, cell-bound
radioactivity was determined. The dissociation constant, Kd, and
number of binding sites, N, at saturation were calculated
(Scatchard, 1949) after subtraction of non-specific binding. To
determine affinities to MHC class II, plasma membranes were
prepared from Raji cells (Massague, 1987). Approximately 108
frozen cells were homogenized in 10 mM Tris-HCl, 1 mM EDTA,
1 mM PMSF, pH 7, containing 0.25 M sucrose with 20 strokes in
a pre-cooled Dounce homogenizer and centrifuged 10 min at
6000 rpm. The pellet was resuspended in that buffer with sucrose
and centrifuged. The combined supernatants were layered on top
of a cushion containing 37% w/v sucrose in buffer and centrifuged
at 105 000 g ´ 60 min. The membrane layer was removed, diluted
4 times with buffer and centrifuged at 30 000 g ´ 30 min. The
pellet was resuspended in 1 ml buffer and stored at –70 ˚C. Plasma
membranes were immobilised as described by Vater et al (1995).
Aliquots from fractionated plasma membranes were diluted in 5
mM NaN3 and 1 mM PMSF and distributed on a 96-well Immulon
2 ELISA plate (Dynatech Labs). The plates were dried, unbound
sites blocked for 1 h and washed twice in Tris-buffered saline
containing 3% defatted milk. Serially diluted biotinylated SEA
(long-arm NHS-biotin reagent, Vector Labs) was incubated with
5T4FabV13-SEAD227A, SEA or C242Fab-SEA in blocking buffer
for 5 min and then membranes for 2 h at room temperature.
Detection was carried out using the Vectastain® ABC Kit
(BioRad). 
Immunohistochemistry 
7 histologically characterized samples of NSCLC (5 adenocarci-
noma and 2 squamous cell carcinoma) were from Dr Jayant Shetye
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(see Table 1) and breast tumours were provided by the Department
of Surgery, Lund University Hospital. Acetone fixed cryosections
of the above tissues were labelled with 5T4FabV13SEAD227A
followed by biotinylated rabbit anti-SEA (in house production).
After incubation in streptavidin-biotin/horseradish peroxidase
(Dako, Copenhagen) the sections were developed in diaminoben-
zidine (Saveen AB, Malmö), counterstained in methyl green and
mounted. As reference to reaction seen in vessels anti human CD31
antibody was used (Dako, Copenhagen). As negative controls irrele-
vant FabSEAD227A and mouse monoclonal IgG1 were used. 
In vivo induction of cytokines 
All animal were kept under pathogen-free conditions and the
experiments carried out using approved ethical protocols.
C57/B16 mice got 4 daily intravenous injections of 30 ug control
Fab-SEA or 5T4FabV13-SEAD227A in PBS or buffer alone. Blood
samples were taken by caval vein puncture at various time points.
All groups contained pooled sera from 3 animals. The levels of
IL-2, IL-6, TNF-a and IFN-g were measured as above. 
Therapy in SCID mice 
Severe Combined Immunodeficient (SCID) female mice (C.B-17,
Bommice, Ry, Denmark) were injected intraperitoneally with 3 ´ 106
Calu-1 cells in vehicle (0.2 ml PBS-1%Balb/c mouse serum) and 5
days later I.P. with 3 ´ 106 PBMC in 0.2 ml vehicle. 1 to 2 h after
injection of PBMC all mice were injected intravenously with
5T4FabV13-SEAD227A or the non-binding control C215Fab-
SEAD227A (Hansson et al, 1997) in 0.2 ml vehicle or vehicle alone.
2 additional intravenous injections of the respective test substance
were given with 3 day intervals unless otherwise specified. The
mice were sacrificed between day 30 to 40, by cervical dislocation
and the number of tumours and the tumour mass determined.
Tumours of less than 5 mg were estimated as 2 mg, tumours with a
mass of more than 5 mg and less than 10 mg as 7 mg and tumours
larger than 10 mg with the actual weight. All tumours larger than 1
mg were counted. Each treatment cohort contained 5 to 7 mice to
permit comparison to other treatment cohorts treated simultane-
ously with the same batch of effector cells. Statistical significance
was determined by the Mann–Whitney U test. For histochemical
analysis, 6 mm cryosections were analysed as above. 
RESULTS 
E. coli production of the fusion protein 
The fusion protein 5T4FabV13-SEAD227A (Figure 1A) was
produced as a secreted product in E. coli. The product was
expressed as bicistronic construct with SEAD227A fused to the C-
terminus of the Fab heavy chain. The production level was
increased 15-fold by replacing 7 amino acid residues in the frame-
work of 5T4Fab, yielding 5T4FabV13 (Forsberg et al, 1997). The
yield in the E. coli growth medium of 5T4FabV13-SEAD227A was
in the order of 0.5 g l–1. To decrease the MHC class II binding, and
subsequently in vivo toxicity, the replacement Asp227Ala was
introduced in SEA, yielding SEAD227A (Abrahmsén et al, 1995).
The full-length product was recovered in a 2-step purification
procedure. The purity of the product was at least 95% as deter-
mined by SDS-PAGE and chromatographic techniques. In addition
to the full-length product, a truncated variant corresponding to
5T4V13Fab, was recovered in the second purification step. 
Tissue reactivity of 5T4FabSEAD227A
The expression of 5T4 antigen in tumour and normal tissue was
investigated with immunohistochemistry. 5T4FabV13-SEAD227A
Treatment of NSCLC with a tumour-targeted superantigen 131
British Journal of Cancer (2000) 85(1), 129–136 © 2001 Cancer Research Campaign
VH 5T4 CH C242
VL 5T4(V13) CL C242
SEA
D227A
A
Figure 1 (A) Schematic representation of 5T4FabV13-SEAD227A. The product consists of a modified variant of the variable regions from 5T4 antibody
(Forsberg et al, 1997) connected to the CL and CH1 domains of the antibody C242 (Dohlsten et al, 1994). The superantigen SEAD227A is fused to the C-terminus
of CH1. (B) Immunohistochemical analysis of the 5T4-antigen expression in NSCLC tumour tissue and breast cancer tissue. Strong expression is observed on
both the tumour cells (T) as well as in the stroma (S) 
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Btumour reactivity was demonstrated in 7/7 cases of NSCLC,
including 5 adenocarcinomas and 2 squamous cell carcinomas
(Table 1). Moderate staining was seen in 4 of the adenocarci-
nomas and 1 squamous cell carcinoma and moderate to strong
in the remaining. In a group of 6 breast carcinomas, moderate
reactions were seen in 5 of them and a moderate–strong in the
sixth. Reaction was not only confined to the tumour cells since
all examined tumours (both NSCLC and breast carcinomas)
also showed stromal reactivity (Figure 1B). In some cases the
stromal reaction dominated over the tumour cell reaction.
5T4FabV13-SEAD227A reactivity was also assessed in some
normal tissues (Table 1) and was found to be similar to that seen
with the mAb (Southall et al, 1990). This reactivity was not
observed with an irrelevant FabSEAD277A protein. The normal
tissue reactivity is presented in Table 1. The most quantitatively
dominating normal tissue reactivity was found in some cell type
or extra-cellular component found in association with the basal
membrane or the lamina propria of the alimentary tract. Focally
weak reaction was seen in the luminal outline of a minority
(less than 10%) of muscular blood vessels in different normal
tissues. This reaction showed individual variation since only
2/4 colon samples, 2/4 lung and 2/4 myocardial samples demon-
strates it. 
In kidney 2/4 showed weak diffuse, possibly intracellular
reaction in glomeruli and outlining of the parietal layer of
Bowman’s capsule while the other 2 showed weak–moderate
reaction in these structures. In the liver 1/3 samples showed a
weak staining outlining sinusoids proximal to the central vein.
Weak–moderate reaction was also found in duct epithelium of
pancreas and in squamous epithelium of pharynx and weak
reaction was found in the epidermal layer of the skin and
in association with the follicular epithelium of the thyroid
gland. 
Binding affinity of 5T4FabV13-SEAD227A to the 5T4
antigen and MHC class II 
Several cell lines were investigated for 5T4 antigen expression
using flow cytometry and the strongest 5T4 FACS positive
NSCLC line, Calu-1, was used to measure the affinity of the
fusion protein to the 5T4 antigen. In FACS analysis, the fusion
protein 5T4FabV13-SEAD227A bound to the cells in a dose-
dependent manner with maximum binding at 10–8 M (data not
shown). Radioiodinated 5T4FabV13-SEAD227A and 5T4FabV13
were used for the antigen-binding assays. Figure 2A shows that
both reagents have nM affinity (mean KD of 1.2 ´ 10–9 M or 2.3
´ 10–9 M respectively) with an antigen density of approximately
3 ´ 105 molecules per cell. Binding of 5T4FabV13-SEAD227A
was also measured on ME 180 cells. Here, the affinity was
slightly higher, 0.7 ´ 10–9 M, while the number of binding sites
were approximately 1.3 ´ 105 molecules per cell (data not
shown). 
The binding to MHC class II expressed on Raji cells was then
investigated. In accordance with previous findings (Dohlsten et al,
1994), Fab-SEA was a much weaker competitor for binding to
MHC class II molecules than SEA. SEA and Fab-SEA showed
IC50 values of approximately 21 and 360 nM respectively in a
competitive assay with biotinylated SEA to coated Raji cell
plasma membranes. 5T4FabV13-SEAD227A did not show any
displacement in the concentration range used (≤ 20 mM) and thus
has an affinity of less than 10 mM (Figure 2B). 
Cytotoxicity of 5T4FabV13-SEAD227A to NSCLC and MHC
class II-expressing cells 
To investigate T-cell mediated cytotoxicity on tumour cells
induced by the fusion protein in vitro, 5T4FabV13-SEAD227A was
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Table 1 Summary of the immunohistochemical analysis of NSCLC, breast cancer and normal tissue. The tissue-reactivities were scored semiquantitatively
according to the intensity of the staining. A + equals weak reaction, ++ moderate reaction and +++ strong reaction 
Tissue Reactivity Comment 
NSCLC (n = 7) ++ –+++ Homogenous staining in 7/7 samples, 5 adenocarc. and 2 squamous carc. 
Breast ca. (n = 6) ++ –+++ Homogenous staining in 6/6 samples.
CNS (n = 1) neg. 
Skin (n = 2) neg. 
Myocardium (n = 4) + Reaction in the luminal outline of a subpopulation of muscular vessels in 2/4 samples. 
Adrenal (n = 2) neg. 
Kidney (n = 4) + –++ Weak-moderate diffuse reaction in glomeruli and parietal layer outlining Bowman’s capsule (2/4).
Weak focal reaction outlining lumen in occasional muscular vessels (2/4). 
Lung (n = 4) + –++ Weak luminal outline in occasional vessels (2/4). Moderate reaction in a basal epithelial cellular or 
matrix component associated with the bronchial epithelium.
Liver (n = 4) + Occasional staining of the sinusoidal outline close to the central vein (1/4). 
Pancreas (n = 2) + –++ Weak-moderate reaction in occasional pancreatic ducts and scarce stroma structures. Weak focal
reaction outlining lumen in occasional muscular vessels. 
Gastro-intestinal tract  ++ Reaction in some cell type or extracellular component of the epithelial basal lamina or the lamina
(stomach n = 2, small  propria in parts of the surface epithelium
intestine n = 2 and large
intestine n = 4)
Pharynx (n = 2) + –++ Reaction in squamous epithelium (most prominent in basal layer). 
Thyroid (n = 2) + Reaction associated with follicular epithelial cells. Focal reaction outlining lumen of occasional 
muscular vessels. 
Spleen (n = 2) + Focal reaction outlining lumen of occasional muscular vessels. mixed with chromium labelled Calu-1 cells and human SEA
reactive T cells (Dohlsten et al, 1991). 5T4FabV13-SEAD227A
mediated a specific T cell killing of Calu-1 cells (Figure 3A) and
was 105 times more effective than control Fab-SEAD227A, as
determined by the EC50 value. The EC50 was approximately 10–12
M for 5T4FabV13-SEAD227A and no cytotoxicity was observed in
the absence of T cells. 5T4FabV13-SEAD227A was also tested for
the ability to mediate MHC class II-dependent superantigen-
mediated cytotoxicity against chromium-labelled Raji cells
(Figure 3B). 5T4FabV13-SEAD227A had about 100 times reduced
MHC class II-dependent cytotoxicity compared to control Fab-
SEA, as judged by the EC50 value. This reflects the lowered
affinity to MHC class II by the D227A substitution in SEa. In
this assay, the EC50 value of 5T4FabV13-SEAD227A was approxi-
mately 10–10 M.5T4FabV13-SEAD227A had similar activity as the
control Fab-SEAD227A. 
In vivo immune activation of 5T4FabV13-SEAD227A
In order to quantify the systemic immune response by Fab-
SEAD227A relative to Fab-SEA proteins, we analysed the serum
levels of a panel of cytokines in C57/B16 mice injected with the
same dose Fab-SEA and 5T4FabV13-SEAD227A. There is a correla-
tion between the systemic cytokine levels and systemic toxicity for
Fab-SEA constructs in both mice and humans (Dohlsten et al,
1995b; Alpaugh et al, 1998). Repeated injections of Fab-SEA
resulted in strong production of IL-2, IFN-g, TNF-a and IL-6
(Figure 4). Drastic reduction in the systemic levels of all tested
cytokines was seen when comparing the effects of Fab-SEA with
5T4FabV13-SEAD227A. A 10-to 100-fold reduction in the serum
levels of IL-2 and IFN-g and a 100 to 1000 reduced amount of
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Figure 2 (A) Representative Scatchard plot and saturation curve for binding
of 125I-5T4FabV13-SEAD227A (u) and 125I-5T4FabV13 (l) to Calu-1 cells.
Values are corrected for non-specific binding. The calculated Kd in this
experiment were 1.2 and 2.3 nM respectively with 300 000 sites/cell. Each
point represents the mean of triplicates. (B) Binding of 10 nM biotinylated
SEA to immobilized MHC class II positive Raji cell plasma membranes in the
presence of SEA (s), C242Fab-SEA (Dohlsten et al, 1995b) (n) or
5T4FabV13-SEAD227A (u) as competitors. Each point represents the mean of
duplicates 
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Figure 3 Induced cytotoxicity using 5T4FabV13-SEAD227A on (A) chromium-
labelled 5T4 expressing Calu-1 cells and (B) chromium-labelled MHC class
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BTNF-a and IL-6 was recorded in animals treated with
5T4FabV13-SEAD227A (Figure 4). In fact, the levels of IL-2 and
TNF-a were below the level of detection for the assay using the
superantigen analogue. Thus, the replacement in the MHC class II-
binding region in SEA results in a drastic reduction in the systemic
levels of cytokines in the murine system. 
Therapy of human NSCLC with 5T4FabV13-SEAD227A in
humanized SCID mice 
To investigate 5T4FabV13-SEAD227A therapy against human
NSCLC cells, a SCID-mouse model was developed. Calu-1 cells
were tested for intraperitoneally growth in the mice (data not
shown) and kinetic analysis showed an increased tumour growth
during the first 30 days. All tumours were found to be 5T4 antigen
positive using immunohistochemical staining 9, 10 and 25 days
after transplantation. Using systemic intravenous treatment,
5T4FabV13-SEAD227A was given 3 times with 3 day intervals of
mice grafted with human PBMC, a strong suppression in Calu-1
tumour mass and number was obtained (Figure 5). More than 85%
reduction in the number of tumours and more than 95% reduction
in tumour mass, calculated as described in Materials and methods,
were observed. No significant therapy was observed with a control
fusion protein not binding to the Calu-1 tumour, indicating that the
therapy involves specific targeting to 5T4 positive tumour cells.
Significant tumour therapy was only observed when treating with
5T4FabV13-SEAD227A in the presence of PBMC (Figure 5). The
5T4FabV13-SEAD227A therapy was dose-dependent requiring 10
mg/injection or more for a significant effect. Depending on the T-
cell donor however, significant therapy can sometimes be seen
with 1 mg/injection of 5T4FabV13-SEAD227A (data not shown). 3
or more injections of 5T4FabV13-SEAD227A were required for
optimal tumour therapy in the humanised SCID mice (Figure 5).
Significant therapy of Calu-1 growth was obtained against 4, 5-
and 8-day-old established tumours (Figure 5). A more than 85%
reduction of tumour weight was observed on 8-day-old established
tumours. 
Thus, significant dose-dependent tumour therapy against estab-
lished NSCLC tumours growing in humanized SCID mice was
obtained with 5T4FabV13-SEAD227A. 
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Figure 5 Therapy of SCID-mice carrying human Calu-1 tumours. (A) Dose titration, (B) effects of therapy on day 4, 5 and 8 tumours and (C) increased effects
are observed using repeated injections of 5T4FabV13SEAD227A. 5T4FabV13-SEAD227A was active even on day 8 tumours, but only in the presence of PBM. Best
effects were observed after repeated injections 
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CDISCUSSION 
NSCLC is associated with a poor prognosis since the beneficial
effects of the available therapies are limited. Current therapeutic
protocols include surgery and chemotherapy, but despite recent
improvements most advanced stage patients die of the disease.
However, it has clearly been shown that human non-small-cell
lung cancer tissue contain tumour-infiltrating lymphocytes that
upon activation releases tumoricidal cytokines (Ortegel et al,
2000). Thus, the fusion protein 5T4FabV13-SEAD227A represents a
novel and attractive approach for therapy of NSCLC. The
5T4FabV13 has a high affinity for the antigen and can therefore be
used for efficient targeting of superantigens to the tumour tissue.
The SEA variant used has very potent T cell activating as well as
cell killing properties and it has been modified to reduce systemic
toxicity. Fusing the superantigen and 5T4FabV13 has not signifi-
cantly altered their individual properties and the recombinant
product can be produced at very high levels in E. coli, which is not
always the case of recombinant antibody fragments (reviewed by
Hudson, 1998). The favourable reactivity of the 5T4 antigen in all
tested NSCLC and breast carcinomas in combination with the low
normal tissue reactivity suggests that these types of cancer cells
constitute good targets for the fusion protein. Also, the tumour
stroma contained large amounts of the 5T4 antigen (Figure 1) and
may therefore be an additional target for the fusion protein. Whether
the binding of 5T4FabV13-SEAD227A to stromal cells contributes in
the eradication of solid tumours remains to be studied. Most of the
normal tissue reactivity found was found to be weak and focal/-
diffuse. The reaction associated to the gastro-intestinal tract is the
most prominent. However, the nature of this reactivity, whether it
is cell-bound, cell surface associated or extracellular can not be
concluded from light microscopy analysis and thus it is not
possible to make predictions of 5T4FabV13-SEAD227A targeting to
these structures in vivo. This is also the case for the reaction seen
in association to lung bronchial epithelium. In a previous clinical
phase I study, no obvious organ-related side effects were seen in
cancer patients using C242FabSEA (Alpaugh et al, 1998) which
binds strongly to MHC class II as well as to normal colon tissue. 
Treatment of certain neoplastic disease with monoclonal anti-
bodies is effective. Very encouraging data has been presented for
B-cell malignancies (McLaughlin et al, 1998), colorectal cancer
(Riethmüller et al, 1998) as well as Her-2 positive breast cancer
(Goldenberg, 1999). Traditionally murine antibodies were used,
but more recently human or humanized antibodies have shown to
have advantages. There is an intense focus on other antibodies in
the preclinical or early clinical phase, but there are also activities
ongoing to further potentiate the successful antibodies using
radioisotopes, cytotoxic fusion partners or by making the anti-
bodies bispecific. Targeting of superantigens has previously been
described for colon cancer therapy (Dohlsten et al, 1994, 1995b).
This therapy leads to infiltration of T-cells in the tumour tissue
(Dohlsten et al, 1995a, Litton et al, 1996). Superantigen therapy
stimulates both CD4+ and CD8+ T-cells (Dohlsten et al, 1995a)
that have potent cytotoxic properties to directly kill target cells, but
secondary effects such as cytokine secretion and recruitment of
other effector cells may be of even higher importance for
successful therapy. These secondary events are important to kill
sub-populations of cancer cells not expressing the antigen.
Targeting of wild-type SEA has been investigated in phase I clin-
ical studies for colon cancer therapy (Alpaugh et al, 1998).
Preclinical data also suggest that these already powerful molecules
can be further potentiated by the simultaneous targeting of IL-2 to
the tumour tissue (Rosendahl et al, 1999; Soegaard et al, 1999).
Studies using bispecific antibodies and staphylococcal enterotoxin
B (Rice et al, 1999), show that this combination induce anti-
tumour immunity and since 5T4FabV13-SEAD227A uses similar
immunological principles for therapy, it is tempting to speculate
that also here a T-cell memory is induced. 
The structure and function properties of SEA have been well
characterized (Abrahmsén et al, 1995; Hudson et al, 1995; Schad
et al, 1995). To reduce the systemic toxicity, a major drawback in
the use of wild-type SEA (Alphaug et al, 1998), a substitution of
Asp 227 has been made. This residue co-ordinates a Zn2+ ion to
form a high affinity binding site to the b-chain of MHC class II.
However, binding to MHC class II is important to obtain inflam-
matory cytokines and to activate T-cells. Therefore, the second
MHC class II binding site surrounding Phe 47 was not altered. The
biological consequences of this replacement is that the soluble
fusion protein is less potent in activating resting T cells and stimu-
lating cytokine production, due to a lower MHC class II affinity.
Although the mouse is much less sensitive to SEA-induced
immune activation, our data clearly demonstrates the relative
potency difference in the mutated superantigen construct. This
difference has been confirmed in other species such as the rabbit
and monkey (data not shown), and supporting data are being
obtained in humans. However, the fusion protein is equally very
active when presented on a cell surface via the 5T4-antigen.
Therefore, it is anticipated that the product will be very potent
locally, e.g. in the tumour, while being less potent in systemic 
T-cell activation. Also, targeting to tissues such as the spleen is less
pronounced with the mutated superantigen (Hansson et al, 1997).
One important attribute of SEA therapy is that it does not
depend on the MHC-restricted T-cell recognition of peptide anti-
gens where evasion of natural or induced CTLs may occur by
down-regulation of HLA class I expression (Keating et al, 1995;
Gariddo et al, 1997). There are now several well-established
examples of such immune escape in the natural history of
neoplasia (Bontkes et al, 1998, 1999) and there is little doubt that
this presents a major problem for cancer vaccine therapies aimed
at inducing CTL responses. 
In conclusion, 5T4FabV13-SEAD227A combines excellent
tumour cell-binding properties with the powerful cytotoxic proper-
ties carried by the superantigen and represents a novel type of
therapy against non-small-cell lung cancer. The 5T4FabV13-
SEAD227A is currently investigated in a phase I clinical study in
NSCLC patients. 
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